Department of Nutritional Sciences, King's College London, London, UK; Department of Nutrition & Dietetics, King's College Hospital NHS Foundation Trust, London, UK.
Department of Nutrition & Dietetics, King's College Hospital NHS Foundation Trust, London, UK.
Clin Nutr. 2023 Nov;42(11):2159-2172. doi: 10.1016/j.clnu.2023.09.010. Epub 2023 Sep 24.
BACKGROUND & AIMS: Medium-chain triglyceride (MCT) supplementation is recommended in cholestatic liver disease, despite unclear evidence and no consensus on the ideal percentage of fat that should be MCT. The aim was to undertake a scoping review to identify the extent and type of evidence regarding how MCT supplementation, and percentage of MCT, affects fat absorption, growth, nutritional status and clinical outcomes (morbidity, mortality, transplant) in children with cholestatic liver disease.
Nine databases (MEDLINE, Embase, CINAHL, PubMed, AMED, Cochrane Library, Global Health, Scopus, Proquest) were searched from inception, with hand-searching conference abstracts and forward/backward citation searching. Eligible studies investigated oral/enteral MCT supplementation in children under 18y with cholestatic liver disease. There were no language limits. Two reviewers performed screening and data extraction independently. Data were synthesised narratively.
Following title/abstract screening (1202 studies) and full-text review (40 studies), 24 studies were included comprising three small RCTs (n = 19 patients), one non-randomised controlled trial (n = 2), seven uncontrolled trials (n = 83) and thirteen case series/reports (n = 211). Seventeen studies were published before 1994. Outcomes included absorption, growth and nutritional status. MCT supplementation was associated with greater fat absorption (9/9 studies) and improved growth in some children (2/4). Higher percentage MCT was associated with greater magnesium and calcium absorption (1/1), essential fatty acid (EFA) deficiency (4/4), but not growth (3/3).
The limited, mostly observational evidence from >30 years ago points to greater fat absorption on MCT and EFA deficiency on very high percentage MCT. High quality RCTs are required, particularly examining the impact of MCT at different percentages on growth, nutritional status and clinical outcomes.
尽管对中链甘油三酯(MCT)补充的疗效证据并不明确,也尚未就脂肪中 MCT 的理想比例达成共识,但仍推荐在胆汁淤积性肝病中使用 MCT 补充剂。本研究旨在进行范围界定综述,以确定有关 MCT 补充剂及其 MCT 比例如何影响胆汁淤积性肝病儿童脂肪吸收、生长、营养状况和临床结局(发病率、死亡率、移植)的证据的范围和类型。
从建库起,检索了 9 个数据库(MEDLINE、Embase、CINAHL、PubMed、AMED、Cochrane 图书馆、全球健康、Scopus、Proquest),并进行了会议摘要的手工检索和引文的向前/向后检索。纳入研究调查了 18 岁以下患有胆汁淤积性肝病的儿童口服/肠内 MCT 补充剂。无语言限制。两名审查员独立进行筛选和数据提取。数据以叙述性方式进行综合。
在标题/摘要筛选(1202 项研究)和全文审查(40 项研究)后,纳入了 24 项研究,包括三项小型随机对照试验(n=19 例患者)、一项非随机对照试验(n=2 例)、七项非对照试验(n=83 例)和十三项病例系列/报告(n=211 例)。其中 17 项研究发表于 1994 年之前。研究结局包括吸收、生长和营养状况。MCT 补充与更高的脂肪吸收相关(9/9 项研究),并在一些儿童中改善了生长(2/4 项研究)。更高比例的 MCT 与更高的镁和钙吸收相关(1/1 项研究)、必需脂肪酸(EFA)缺乏(4/4 项研究),但与生长无关(3/3 项研究)。
30 多年前的有限、主要为观察性证据表明,MCT 可增加脂肪吸收,而极高比例的 MCT 会导致 EFA 缺乏。需要高质量的 RCT,特别是研究 MCT 在不同比例下对生长、营养状况和临床结局的影响。